Botanix Pharmaceuticals Limited (BXPHF) Price & Analysis

2 Followers

BXPHF Stock Chart & Stats

$0.02

$0.02(142.31%)

At close: Jul 29 4:00 PM EDT

$0.02

$0.02(142.31%)

Day’s Range― - ―

52-Week Range$0.01 - $0.11

Previous CloseN/A

Volume114.00K

Average Volume (3M)21.75K

Market Cap

$28.81M

Enterprise Value$34.48M

Total Cash (Recent Filing)$36.63M

Total Debt (Recent Filing)$14.74M

Price to Earnings (P/E)―

Beta-0.48

Next Earnings

Mar 03, 2027

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding2,761,546,100

10 Day Avg. Volume1,500

30 Day Avg. Volume21,750

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.65

Price to Sales (P/S)1.19

P/FCF Ratio-0.64

Enterprise Value/Market Cap1.20

Enterprise Value/Revenue1.00

Enterprise Value/Gross Profit-0.58

Enterprise Value/Ebitda-0.51

Forecast

1Y Price Target

$0.40

Price Target Upside1887.85% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)$41.23M

Bulls Say, Bears Say

Bulls Say

Revenue AccelerationRevenue acceleration is evidence that the company’s products or commercial activities are gaining traction, with annual sales rising about 57% to $34.5M in 2026. If sustained, this expanding base can improve operating leverage and support a path toward more durable economics.

Reduced LeverageDebt reduction materially improves financial flexibility and lowers the balance-sheet burden compared with the prior year. Combined with approximately $63.5M of stockholders’ equity and $106.0M of assets, this provides a stronger base for funding operations and development.

Focused Therapeutic ScopeA defined focus on dermatology, infectious disease, and topical treatments gives Botanix a clear therapeutic scope rather than an undifferentiated development strategy. Concentrating resources in these areas may support specialized execution as products advance through clinical and regulatory stages.

Bears Say

Heavy Cash BurnLarge, recurring cash outflows are a durable constraint because they require the company to keep funding operations before reaching sustainable profitability. Continued negative operating and free cash flow may increase reliance on external capital and limit flexibility for development investment.

Persistent Operating LossesPersistent operating and net losses show that revenue growth has not yet translated into a sustainable earnings model. Ongoing losses can consume the equity base, constrain reinvestment choices, and leave future financial performance dependent on substantial improvement in margins and scale.

Unstable Gross ProfitabilityA deeply negative gross profit indicates that the economics of reported revenue are currently unstable, not merely that corporate overhead is high. Until gross profitability becomes consistently positive, additional sales may fail to generate sufficient contribution toward operating costs and cash needs.

Botanix Pharmaceuticals Limited News

Botanix Sets 2026 AGM Date as Governance Milestones Align with Sofdra Push

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an update. Botanix Pharmaceuticals has scheduled its 2026 Annual General...

12d ago

Botanix Director Increases Equity Stake via Performance Rights Conversion

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an announcement. Botanix Pharmaceuticals has disclosed a change in director...

21d ago

Botanix seeks ASX quotation for 24.9 million new shares

The latest announcement is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals has applied for quotation...

21d ago

S&P Dow Jones Indices Unveils September 2026 Rebalance of S&P/ASX Benchmarks

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has issued an announcement. S&P Dow Jones Indices has announced its September...

1M ago

Botanix Updates Director Patricia Walker’s Equity Holdings After Option Expiry

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has issued an announcement. Botanix Pharmaceuticals has disclosed a change in director...

1M ago

Botanix Pharmaceuticals Options Lapse, Streamlining Capital Structure

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an update. Botanix Pharmaceuticals Ltd has reported the lapse of...

1M ago

Botanix Pharm: Strong Sofdra Adoption and Margin Upside Support Buy Rating with Unchanged $1 Price Target

Botanix Pharmaceuticals Limited, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis...

2M ago

Botanix files updated ASX corporate governance statement for 2026

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an announcement. Botanix Pharmaceuticals has lodged its updated corporate governance...

2M ago

Botanix Revenue Surges on Sofdra Launch as Loss Narrows

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an update. Botanix Pharmaceuticals reported a sharp increase in revenue...

2M ago

Botanix Issues 14 Million Unquoted Performance Rights Under Incentive Plan

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an update. Botanix Pharmaceuticals has notified the market of the...

2M ago

BXPHF FAQ

What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?

Botanix Pharmaceuticals Limited lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.

What is Botanix Pharmaceuticals Limited’s market cap?

Botanix Pharmaceuticals Limited’s market cap is $28.81M.

When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?

Botanix Pharmaceuticals Limited’s upcoming earnings report date is Mar 03, 2027 which is in 141 days.

How were Botanix Pharmaceuticals Limited’s earnings last quarter?

Botanix Pharmaceuticals Limited released its earnings results on Aug 26, 2026. The company reported -$0.007 earnings per share for the quarter.

Is Botanix Pharmaceuticals Limited overvalued?

According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Botanix Pharmaceuticals Limited pay dividends?

Botanix Pharmaceuticals Limited does not currently pay dividends.

What is Botanix Pharmaceuticals Limited’s EPS estimate?

Botanix Pharmaceuticals Limited’s EPS estimate is >-0.01.

How many shares outstanding does Botanix Pharmaceuticals Limited have?

Botanix Pharmaceuticals Limited has 2,761,546,100 shares outstanding.

What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?

Botanix Pharmaceuticals Limited reported an EPS of -$0.007 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in BXPHF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Botanix Pharmaceuticals Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-118.74%

Trailing 12-Months

Asset Growth

-17.91%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.

Botanix Pharmaceuticals Limited (BXPHF) Earnings & Revenues

Historic Earnings Reports

BXPHF Stock 12 Month Forecast

Average Price Target

$0.40

▲(1887.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.697491,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.39756987,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.09764874,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.016,0.06842238461538461,0.12084476923076923,0.17326715384615382,0.22568953846153844,0.27811192307692306,0.3305343076923077,0.3829566923076923,0.4353790769230769,0.48780146153846154,0.5402238461538461,0.5926462307692307,0.6450686153846154,{"y":0.697491,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.016,0.04535152846153846,0.07470305692307691,0.10405458538461537,0.13340611384615383,0.1627576423076923,0.19210917076923073,0.22146069923076922,0.25081222769230765,0.28016375615384614,0.3095152846153846,0.33886681307692307,0.3682183415384615,{"y":0.39756987,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.016,0.022280672307692307,0.028561344615384614,0.034842016923076924,0.04112268923076923,0.04740336153846154,0.05368403384615385,0.05996470615384615,0.06624537846153847,0.07252605076923077,0.07880672307692307,0.08508739538461538,0.0913680676923077,{"y":0.09764874,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.106,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.078,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.079,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.085,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.043,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.019,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.022,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.011,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.015,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.016,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.016,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >